Author: William T Gibson; Daniel M Evans; Jianghong An; Steven JM Jones
Title: ACE 2 Coding Variants: A Potential X-linked Risk Factor for COVID-19 Disease Document date: 2020_4_14
ID: 05w8tv8x_25
Snippet: Procko has done unbiased mutagenesis of the ACE2 regions that bind to the RBD of SRS-312 COV-2, 34 and noted that substitution of Thr27 with hydrophobic residues (e.g. alanine) is expected to 313 increase the ability of aromatic residues of the S protein to pack into the ACE2 interface. Procko proteins are urgently justified. Furthermore, given recent data that human recombinant soluble ACE2 321 (hrsACE2) can block early stages of SARS-CoV-2 infe.....
Document: Procko has done unbiased mutagenesis of the ACE2 regions that bind to the RBD of SRS-312 COV-2, 34 and noted that substitution of Thr27 with hydrophobic residues (e.g. alanine) is expected to 313 increase the ability of aromatic residues of the S protein to pack into the ACE2 interface. Procko proteins are urgently justified. Furthermore, given recent data that human recombinant soluble ACE2 321 (hrsACE2) can block early stages of SARS-CoV-2 infections, 35 any naturally-occurring human ACE2 322 variant that bound more tightly to the viral spike protein might serve as a better "decoy" for the viral 323 protein, and would be a candidate for novel hrsACE2 molecules with therapeutic potential. 324
Search related documents:
Co phrase search for related documents- aromatic residue and SARS infection: 1
- aromatic residue and spike protein: 1, 2, 3
- aromatic residue and viral spike protein: 1
- early stage and RBD bind: 1, 2
- early stage and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- early stage and SARS infection early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- early stage and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- early stage and therapeutic potential: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- early stage and viral spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- hydrophobic residue and SARS infection: 1
- hydrophobic residue and spike protein: 1, 2, 3, 4
- hydrophobic residue and therapeutic potential: 1
- hydrophobic residue and viral spike protein: 1, 2
- naturally occur and RBD bind: 1
- naturally occur and SARS infection: 1
- naturally occur and spike protein: 1, 2, 3
- naturally occur and therapeutic potential: 1
- naturally occur and viral spike protein: 1
- procko protein and spike protein: 1
Co phrase search for related documents, hyperlinks ordered by date